Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.90
Bid: 2.80
Ask: 3.00
Change: 0.05 (1.75%)
Spread: 0.20 (7.143%)
Open: 2.80
High: 2.90
Low: 2.74
Prev. Close: 2.85
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line

Wed, 27th Mar 2024 16:13

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Spectra Systems Corp - Providence, Rhode Island-based authentication technology provider - Reports revenue in 2023 edged up to USD20.2 million from USD19.6 million the year prior. Net income was USD6.0 million, slightly lower than USD6.1 million last time, with diluted earnings per share of 0.13 pence compared to 0.12p. Pays annual dividend of USD0.116 per share, up from USD0.115. Says cash position "remains strong", with cash generation driven by sensor development milestones and prepayments, record sales of covert materials to a central bank, and strong optical materials sales. Believes "that the company is on track to achieve record earnings in 2024."

----------

Infrastructure India PLC - infrastructure fund investing directly into assets in India - Says pretax loss in the six months to September 30 halves to GBP31.6 million from GBP62.2 million the year prior. Basic and diluted loss per share totals 4.77 pence, compared to 5.72p. Says value of investments was GBP99.6 million as at September 30, down from GBP194.1 million the year before.

----------

Metals Exploration PLC - Philippines-focused gold producer - Makes last payment due to the lenders under the mezzanine debt facilities on Monday on the basis of the lower interest rate of 7%, as opposed to 15%, which the company believes should apply under such facilities. Says amount outstanding on the group's senior facility as at Monday stands at USD2,629. Metals Exploration says it has agreed the 7% rate with the majority mezzanine lender, MTL Luxembourg SA. But explains it has been unable to reach agreement as yet, with the minority 29% mezzanine debt lenders, Runruno Holdings Ltd and D & A Holdings Ltd. RHL Group advisers have stated their belief that the higher 15% rate is applicable, which potentially amounts to an additional USD1.9 million owed. But Metals exploration disputes this. Discussions continue. Intends to apply future free cash generated from operations to fund ongoing growth opportunities based on MTL's proven operating track record in the Philippines.

----------

Allergy Therapeutics PLC - Sussex, England-based biotechnology company - Extends cash runway until the first quarter of 2025 following talks with major shareholders SkyGem Acquisition Ltd and Southern Fox Investments Ltd. Lenders agree that a further GBP15 million from the existing GBP40 million amended loan facility, announced on December 27, may be drawn down from the second quarter of 2024. Further, will issue warrants to the lenders following each drawdown under the amended loan facility, entitling the holders to subscribe for new shares at a price of 4 pence each. The entitlement to warrants will be 25 warrants for each GBP1 drawn down under the amended loan facility with a maximum of 1.00 billion warrants. The warrants will be exercisable in whole or in part from July 1 until January 15, 2027. Further, reports pretax loss in the six months to December 31 widens to GBP14.9 million from GBP8.2 million the year prior. Diluted loss per share totals 0.58p compared to LPS of 1.29p. Revenue falls to GBP33.6 million from GBP39.9 million. Explains the decrease in revenue is due to previously reported manufacturing capacity that needed to be allocated to investigational medicinal product batches for use in clinical trials and the ongoing programme of continuous improvement across the supply chain and quality systems paving the way for increased capacity. Demand for the company's products continues to be robust.

----------

Quartix Technologies PLC - Newtown, Wales-based vehicle tracking system provider - Issues trading statement ahead of Wednesday's annual general meeting. Says trading for the first two months of 2024 has been consistent with meeting market expectations for the year. Notes new unit subscriptions for the first quarter of 2024 are expected to be around 10% higher annually. Growth in new subscriptions continues to be led by France and Continental Europe. Further, advises Chief Financial Officer Emily Rees resigns to pursue opportunities outside the company.

----------

Microsaic Systems PLC - Surrey-based developer of real-time mass spectrometers - Reports that having passed quality control specifications, shipments of existing MicroTox reagent stock have begun to meet the demand from clients that are operating Modern Water instruments currently in service. Says stock levels are sufficient to meet this demand until restarted production output from the York facility passes testing and quality control for shipping, as scheduled for April. Further, agrees terms with GX Group, based in Usk Wales, for the continued manufacturing and further development of continuous toxicity monitoring instruments previously sold by the Modern Water business. Acting Executive Chair Bob Moore says: "The combination of Modern Water and Microsaic technologies is underway as planned."

----------

Kingfisher PLC - retailer which owns B&Q and Castorama - Instructs Goldman Sachs International to start the second tranche of the share buy back programme. This will start Wednesday and end no later than June 14. The maximum amount allocated to the tranche will be no greater than GBP50 million. Forms part of overall GBP300 million buy back.

----------

Solid State PLC - Redditch, England-based supplier & design-in manufacturer of computing, power, and communications products - Issues trading update to year ending March 31. Reports a record year with a strong trading performance towards the end of the year. Revenue and adjusted pretax profit are expected to be ahead of consensus expectations. This reflects the recognition of Systems revenue on deliveries in the current financial year. This had previously been expected to be recognised in the financial year to March 2025.

----------

Leeds Group PLC - West Yorkshire, England-based textile manufacturing company - Completes sale of Hemmers-Itex Textil Import Export GmbH. Explains the disposal is deemed to be a sale that divests the company of all, or substantially all of its trading businesses. Therefore, with effect from Tuesday, Leeds is regarded as an AIM Rule 15 cash shell.

----------

LPA Group PLC - Essex-based LED lighting and electro-mechanical systems maker - Issues trading statement at Wednesday's annual general meeting. States first quarter trading has been as anticipated. "Sales levels were largely on target, good order books remain and we are seeing an increased level of activity particularly." Cautions the second quarter "will be affected by late cable shipments which are now coming around the Cape but this will be made up in our third quarter." LPA says "it is clear that the return to profitability will be in our FY25 as some of the growth and profit we were planning for FY24 will have been deferred a further year."

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
27 Mar 2024 11:02

AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
12 Mar 2024 14:06

Allergy Therapeutics starts dosing patients in peanut allergy trial

(Alliance News) - Allergy Therapeutics PLC on Tuesday said it has commenced subcutaneous dosing of peanut allergic patients in its phase 1/2a Protect trial.

Read more
1 Mar 2024 15:49

UK shareholder meetings calendar - next 7 days

Monday 4 March 
Ascent Resources PLCGM re bonus issue of preference shares
JPMorgan Emerging Europe, Middle East & Africa Securities PLCAGM
Lexington Gold LtdAGM
Tuesday 5 March 
Ajax Resources PLCGM re extension of investment mandate
Beowulf Mining PLCGM re capital raise
CC Japan Income & Growth Trust PLCAGM
Driver Group PLCAGM
Edinburgh Worldwide Investment Trust PLCAGM
Jersey Electricity PLCAGM
Wednesday 6 March 
Ecofin Global Utilities & Infrastructure Trust PLCAGM
Mila Resources PLCAGM
Paragon Banking Group PLCAGM
Thursday 7 March 
Asia Strategic Holdings LtdAGM
CT UK Capital & Income Investment Trust PLCAGM
Henderson Opportunities Trust PLCAGM
XPS Pensions Group PLCGM re directors' remuneration policy 2024
Friday 8 March 
Allergy Therapeutics PLCAGM
All Things Considered Group PLCAGM
Chenavari Toro Income Fund LtdAGM
Neo Energy Metals PLCAGM
Schroder UK Mid Cap Fund PLCAGM
Silverwood Brands PLCGM re proposed share capital reduction
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
14 Feb 2024 10:22

Allergy Therapeutics forecasts revenue drop but trials going well

(Alliance News) - Allergy Therapeutics PLC on Wednesday said revenue decreased in its latest half year, and expects to require further funding soon.

Read more
5 Feb 2024 14:09

TRADING UPDATES: Alliance Pharma appoints chair; FireAngel sales down

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
30 Jan 2024 10:38

Allergy Therapeutics resumes trading on AIM; annual revenue plunges

(Alliance News) - Allergy Therapeutics PLC on Tuesday resumed trading on AIM after the release of its annual results.

Read more
27 Dec 2023 14:17

IN BRIEF: Allergy Therapeutics amends facility, plans warrant issue

Allergy Therapeutics PLC - Sussex-based biotechnology company specialising in allergy vaccines - Shares rise as firm enters amendment to the facility agreement it reached in early April with SkyGem Acquisition Ltd and Southern Fox Investments Ltd. Deal provides Allergy Therapeutics with a GBP40 million secured loan facility of which GBP32.5 million is uncommitted. Facility is available to drawdown between January 15 and the same day in 2026, with interest payable semi-annually at 12% per year and a January 15, 2027 repayment date.

Read more
15 Dec 2023 21:09

EARNINGS AND TRADING: Redx full year revenue tumbles; loss widens

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
13 Dec 2023 10:11

Allergy Therapeutics shares jump as hails grass allergy jab data

(Alliance News) - Allergy Therapeutics PLC on Wednesday said that phase-3 trials of its grass allergy injection yielded positive results, moving the product closer to market entry.

Read more
13 Dec 2023 09:55

AIM WINNERS & LOSERS: Impellam climbs on GBP483 million takeover offer

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
14 Nov 2023 11:56

Allergy Therapeutics says allergy therapy trial meets primary endpoint

(Alliance News) - Allergy Therapeutics PLC on Tuesday said that a trial evaluating the efficacy of its subcutaneous allergen-specific immunotherapy candidate has met its primary endpoint.

Read more
14 Nov 2023 10:59

AIM WINNERS & LOSERS: Renalytix revenue halves; DP Poland trades well

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
6 Nov 2023 12:33

IN BRIEF: Allergy Therapeutics extends cash runway until end of 2023

Allergy Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Says it continued to work on initiatives to improve cost control and manage working capital alongside trading broadly in line with expectations for the current financial year to date. Says it has extended its cash runway and anticipates to require additional funding by the end of December. Further, says discussions with some major shareholders regarding a subscription and open offer announced in October have progressed. Says that the pivotal phase 3 grass G306 modified allergen tyrosine adsorbed monophosphoryl lipid A trial remains on track to report interim results this month. Via G306, the company aims to release an immunotherapy for grass allergy.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.